Erasca (ERAS) Competitors

Vericel (NASDAQ:VCEL) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Which has more volatility & risk, VCEL or ERAS?

Vericel has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.

Which has better valuation and earnings, VCEL or ERAS?

Vericel has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$237.22M	7.89	$10.36M	$0.12	309.09
Erasca	N/A	N/A	-$161.65M	-$0.45	-3.54

Do insiders and institutionals have more ownership in VCEL or ERAS?

67.8% of Erasca shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 14.4% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer VCEL or ERAS?

In the previous week, Erasca had 2 more articles in the media than Vericel. MarketBeat recorded 10 mentions for Erasca and 8 mentions for Vericel. Vericel's average media sentiment score of 1.44 beat Erasca's score of -0.05 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer VCEL or ERAS?

Vericel presently has a consensus target price of $60.33, suggesting a potential upside of 62.66%. Erasca has a consensus target price of $4.29, suggesting a potential upside of 168.70%. Given Erasca's higher possible upside, analysts plainly believe Erasca is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Erasca	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Is VCEL or ERAS more profitable?

Vericel has a net margin of 2.85% compared to Erasca's net margin of 0.00%. Vericel's return on equity of 2.47% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	2.85%	2.47%	1.69%
Erasca	N/A	-31.19%	-26.34%

Summary

Vericel beats Erasca on 10 of the 14 factors compared between the two stocks.